Liquidia to Expand PAH Treatment Efforts With RareGen Acquisition
News, PAH News
Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an agreement to acquire the rare disease company and marketer of generic treprostinil ... Read more